Results 171 to 180 of about 23,157 (220)
Some of the next articles are maybe not open access.
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
Journal of Antimicrobial Chemotherapy, 2022 J. Ambrosioni, J. R. Liévano, L. Berrocal, A. Inciarte, Lorena de la Mora, A. González-Cordón, M. Martínez-Rebollar, M. Laguno, B. Torres, A. Ugarte, Iván Chivite, L. Leal, E. de Lazzari, J. Miro, J. L. Blanco, Esteban Martínez, J. Mallolas +16 moresemanticscholar +1 more sourceBictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
The Lancet, 2017 J. Gallant, A. Lazzarin, A. Mills, C. Orkin, D. Podzamczer, P. Tebas, P. Girard, I. Brar, E. Daar, D. Wohl, J. Rockstroh, Xuelian Wei, J. Custodio, K. White, Hal Martin, A. Cheng, E. Quirk +16 moresemanticscholar +1 more sourceFixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.
The Lancet Child & Adolescent Health, 2021 A. Gaur, M. Cotton, C. Rodriguez, E. McGrath, Elizabeth Helström, A. Liberty, E. Natukunda, P. Kosalaraksa, K. Chokephaibulkit, H. Maxwell, Pamela Wong, D. Porter, Sophia R Majeed, Mun Sang Yue, H. Graham, Hal Martin, D. Brainard, C. Pikora +17 moresemanticscholar +1 more sourceEfficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
Lancet, The, 2021 Lee Fairlie, Paul Edward Sax, Lisa M Frenkel +2 moreexaly
